SALT LAKE CITY, July 29, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will issue financial results for the fiscal fourth quarter and full year 2015 and provide a business update following the close of market on Tuesday, August 11, 2015.
The Company also will host a conference call at 4:30 p.m. ET on August 11, 2015 to discuss the financial results. Participating on the call will be Mark Capone, president and CEO and Bryan Riggsbee, chief financial officer.
To listen to the call, interested parties in the United States may dial 800-410-1397 or +1 303-223-2680 for international callers. All callers will be asked to reference reservation number 21772056.
The conference call also will be available through a live webcast at www.myriad.com. A replay of the call will be available two hours after the end of the call for seven days and may be accessed by dialing 800-633-8284 within the United States or +1 402-977-9140 for international callers and entering reservation number 21772056.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where high value diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer markets, diversifying its product portfolio through the introduction of new products and increasing its international contribution. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
Source:Myriad Genetics, Inc.